))
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
Manage episode 408994928 series 3560609
Content provided by Jacqueline Stone and Oncololgy News Central. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and Oncololgy News Central or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for the treatment of men with high-risk features. Dr. Posadas discusses these findings and related advances with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles. They also consider how the growing role of prostate-specific membrane antigen (PMSA) positron emission tomography (PET)-CT is “really impacting” care for patients with prostate cancer who have biochemical recurrence. Dr. Posadas explains why the best approach for patients with negative PSMA PET-CT results who have high-risk features remains “a point of great discussion.”
124 episoade
Distribuie
